In addition, it has been shown that cancer-associated mutations in SETD2 also concern resistance to chemical inhibitors such as Sunitinib, a tyrosine kinase inhibitor commonly used in targeted therapeutics for the treatment of metastatic RCC [105]. This evidence concerns the gene SETD2 and cancer.